ArticleDiabetology & metabolic syndrome2025
Causal effects of primary aldosteronism on inflammation and bone density: evidence from Mendelian randomization, animal, and clinical studies.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStudies on the pro-inflammatory effects of primary aldosteronism (PA) in humans have largely relied on measurements of circulating inflammatory biomarkers and are mostly observational in nature, making it difficult to establish a causal relationship between PA and inflammatory responses. In addition, the association between PA and bone mineral density (BMD) remains controversial and warrants further investigation.
objectiveThis study aimed to evaluate the causal effects of PA on circulating inflammatory proteins and bone mineral density.
methodsWe performed a Mendelian randomization (MR) analysis to assess the causal relationships between PA and 91 circulating inflammatory proteins, as well as BMD at four anatomical sites. The findings were further validated using a rat model and clinical data.
resultsMR analysis revealed significant inverse causal associations between PA and the circulating levels of interleukin-10 receptor subunit beta (IL-10RB) and hepatocyte growth factor (HGF). These findings were further supported by the rat model results, in which serum IL-10RB (2.10 ± 1.18 ng/mL) and HGF (1120.95 ± 144.33 pg/mL) levels in the Aldo-salt group were significantly lower than those in both the Aldo-salt-Epl group (4.80 ± 1.40 ng/mL and 1434.74 ± 192.45 pg/mL, respectively) and the control group (5.07 ± 0.79 ng/mL and 1540.42 ± 316.32 pg/mL, respectively) (P < 0.05). Consistently, clinical data showed that patients with PA had significantly lower serum IL-10Rb and HGF levels compared to those with essential hypertension (EH) (1146.20 ± 178.23 vs. 1660.49 ± 238.44 pg/mL and 1082.93 ± 231.47 vs. 1935.18 ± 296.44 pg/mL, respectively; P < 0.001 for both). Notably, MR analysis did not identify any significant causal associations between PA and bone mineral density at the total body, forearm, femoral neck, or lumbar spine.
conclusionThis study is the first to demonstrate a causal relationship between PA and reduced circulating levels of IL-10RB and HGF, suggesting that PA may promote disease progression by impairing anti-inflammatory defenses and providing new insights for diagnostic and therapeutic strategies targeting inflammation-related pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.